In July, Genentech, a biotechnology company, awarded a $180,000 unrestricted grant to Messengers for Health to promote health equity.
Solo-Dex Nominated for Prestigious 2023 Prix Galien USA Awards
The Galien Foundation has recognized the significant contributions of the Wolf Creek, MT company in the “Best Medical Technology” category.
Inimmune Announces First Subject Dosed in First-in-Human Phase 1 Clinical Trial of its novel intranasal TLR4 agonist, INI-2004, for the Treatment of Allergic Rhinitis and FDA Clearance of IND application for INI-2004
Milestone marks transition of Inimmune Corporation to a clinical-stage company.
New Diagnostic Tests Could Change Leukemia Prevention and Treatment
A Montana based molecular diagnostic company, Alercell Inc., is pioneering novel techniques to augment the way leukemia is diagnosed, treated and ultimately prevented.
Solo-Dex, Inc. Strikes Groundbreaking Agreement for Distribution in Saudi Arabia of its Fascile(R) Non-Opioid Acute Pain Management Suite
Wolf Creek company Solo-Dex, a leading player in the development, manufacture, and sales of innovative non-opioid acute pain management solutions, is pleased to announce a strategic master distribution agreement with CH Trading Group LLC and Farouk, Maamoun Tamer & Co. This groundbreaking partnership will pave the way for the distribution of Solo-Dex’s revolutionary Fascile® suite of products within the Kingdom of Saudi Arabia.
“Fighting like a mother” — UM Neuroscience Hunts Cure for Young Boy
Amber Freed was like any mother looking for answers. Her twins – born in 2017 – were still babies when she and her husband noticed Maxwell wasn’t advancing at the same pace as his sister, Riley. The doctors tried to reassure the family, but Freed knew there was something wrong. Soon the doctors did, too.
Alercell celebrates National Cancer Survivors’ Day® 2023
The National Cancer Survivors’ Day Foundation invites all cancer survivors to celebrate on June 4 and Alercell joins all survivors to celebrate another beautiful day of life. The date marks the 36th annual Celebration of Life.
Tonix Pharmaceuticals Announces Agreement and Initiation of Enrollment in Phase 2 Trial with the University of Washington to Study TNX-1900 (Potentiated Intranasal Oxytocin) for Social Anxiety Disorder
Social Anxiety Disorder Affects 15 Million U.S. Adults and is More Common Among Women than Men
FDA Converts Novel Alzheimer’s Disease Treatment to Traditional Approval
The U.S. Food and Drug Administration converted Leqembi (lecanemab-irmb), indicated to treat adult patients with Alzheimer’s Disease, to traditional approval following a determination that a confirmatory trial verified clinical benefit.